Why AbbVie Could Join the M&A Mania Soon Post author:Sam Post published:January 30, 2018 Post category:BioPharma The company expects to only pay a tax rate of 9 percent this year, which will free up a lot of cash. Source: BioSpace You Might Also Like Allergan Could Bank $1B by Unloading Its Anti-Infectives Biz January 17, 2018 FDA Gives Nod to Johnson & Johnson's Potential Blockbuster Psoriasis Med July 13, 2017 BlueRock Therapeutics Expands Toronto Presence With R&D And Manufacturing Hub, Appoints Key R&D Leadership August 16, 2017
BlueRock Therapeutics Expands Toronto Presence With R&D And Manufacturing Hub, Appoints Key R&D Leadership August 16, 2017